Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HB-0034 by Huabo Biopharm (Shanghai) for Pyoderma Gangrenosum: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Pyoderma Gangrenosum. According to GlobalData,...
HB-0034 by Huabo Biopharm (Shanghai) for Hidradenitis Suppurativa: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Hidradenitis Suppurativa. According to GlobalData,...
HB-0034 by Huabo Biopharm (Shanghai) for Squamous Cell Carcinoma: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Squamous Cell Carcinoma. According to...
HB-0034 by Huabo Biopharm (Shanghai) for Systemic Lupus Erythematosus: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Systemic Lupus Erythematosus. According to...
HB-0034 by Huabo Biopharm (Shanghai) for Ulcerative Colitis: Likelihood of Approval
HB-0034 is under clinical development by Huabo Biopharm (Shanghai) and currently in Phase I for Ulcerative Colitis. According to GlobalData,...